Definitive Contract HHSN261201200047C

This federal contract award was issued by the National Cancer Institute (NCI), a civilian agency, to Insight Genetics, Inc., a small business. The $193,637 firm-fixed-price contract is for the development of a clinical diagnostic assay to detect ALK inhibitor resistance mutations under the SBIR (Small Business Innovation Research) program. The contract has a period of performance through July 31, 2012 and was awarded on September 30, 2011. As an SBIR award, this contract was set aside for...

This is a $1,698,988.00 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), which is part of the U.S. Department of Health and Human Services (HHS), to Insight Genetics, Inc., a small business. The contract is for "OTHER FUNCTIONS - R & D BIOMEDICAL (BASIC RESEARCH)" and has a total small business set-aside designation. The contract was awarded on September 20, 2012 and has an ultimate completion date of August 16, 2015. This contract award is not associated...

The U.S. National Cancer Institute (NCI) awarded a $1,499,990.00 cost-plus-award-fee contract to Insight Genetics, Inc. for research and development in the biomedical basic research field. The contract, which has a performance period through September 19, 2015, was awarded on September 20, 2013 and does not have a set-aside designation. While the original solicitation is not provided, this contract appears to be part of the NCI's larger research and development efforts in the medical and...

<p>The U.S. National Cancer Institute awarded a $200,000.00 firm fixed-price definitive contract to Insight Genetics, Inc., a small business, on September 30, 2010. The contract has a completion date of May 3, 2011 and was set aside for small businesses. The contract is for research and development services related to the National Cancer Institute's work, performed in Nashville, Tennessee.</p>

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Personal Genome Diagnostics Inc., a for-profit company that provides molecular tissue testing services to federal agencies. The contract has a ceiling value of $222,994.00 and is a firm-fixed-price definitive contract for the development of a non-invasive approach to assess mutation load in tumors for treatment with...

<p>This is a $13,290,090.00 cost-no-fee definitive contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Alnis Biosciences Incorporated for the development of &quot;NOVEL TECHNOLOGIES FOR NONINVASIVE DETECTION, DIAGNOSIS, AND TREATMENT OF CANCER.&quot; The contract was awarded on September 30, 2004 with a period of performance ending on March 31, 2008. This contract does not have a set-aside designation.</p>

This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Incogen Inc., a woman-owned small business. The contract, valued at $3,599,936, is for the development of &quot;GENE EXPRESSION SIGNAL PROCESSING TOOLS FOR EARLY DETECTION OF CANCER&quot; under Topic 197. It is a definitive, firm-fixed-price contract with a period of performance ending on December 14, 2009. The contract is set aside for small businesses.

This is a $37,262,683.59 definitive cost-no-fee contract awarded by the National Cancer Institute (NCI) to The International Genomics Consortium. The contract is for providing biospecimen processing services to support the Cancer Genome Atlas (TCGA) program, which is part of the National Institutes of Health's efforts to comprehensively characterize various cancer types. The contract has an ultimate completion date of December 30, 2012 and was awarded on September 24, 2010 as part of the...

This is a firm fixed-price delivery order awarded by the National Cancer Institute (NCI), a civilian federal agency, to Ilsbio LLC, a for-profit limited liability company. The contract is for the recovery of tissue samples and data from various types of cancer to support the Cancer Genome Atlas (TCGA) program. This award is part of the NCI Cancer Genome Atlas Program Tissue Purchase master IDIQ contract and is funded under the American Recovery and Reinvestment Act (ARRA). The contract has a...

This is a $199,987.00 firm fixed price definitive contract awarded by the National Cancer Institute, a civilian agency, to Genome Data Systems Inc., a minority-owned, small disadvantaged business, for &quot;OTHER FUNCTIONS GENOME &quot;PHASE I, TOPIC 309, LABEL FREE MULTIVARIATE CANCER DIAGNOSIS&quot;&quot;. The contract has a total small business set-aside designation and was awarded on September 28, 2012, with a completion date of June 27, 2013. Genome Data Systems Inc. has previously received...